Distribuzione geografica
Continente #
NA - Nord America 4.475
EU - Europa 737
AS - Asia 323
AF - Africa 9
Continente sconosciuto - Info sul continente non disponibili 3
SA - Sud America 2
Totale 5.549
Nazione #
US - Stati Uniti d'America 4.466
IT - Italia 226
UA - Ucraina 167
CN - Cina 153
DE - Germania 95
IE - Irlanda 75
VN - Vietnam 64
IN - India 58
SE - Svezia 40
TR - Turchia 27
GB - Regno Unito 26
BE - Belgio 25
FI - Finlandia 20
CH - Svizzera 15
RO - Romania 13
CA - Canada 9
IR - Iran 9
RU - Federazione Russa 7
FR - Francia 6
JP - Giappone 6
NL - Olanda 6
PL - Polonia 6
TG - Togo 4
EE - Estonia 3
EG - Egitto 3
EU - Europa 3
CZ - Repubblica Ceca 2
ES - Italia 2
HK - Hong Kong 2
AT - Austria 1
BG - Bulgaria 1
BR - Brasile 1
CM - Camerun 1
CO - Colombia 1
IL - Israele 1
KR - Corea 1
MN - Mongolia 1
NG - Nigeria 1
RS - Serbia 1
SG - Singapore 1
Totale 5.549
Città #
Fairfield 716
Ashburn 489
Chandler 446
Woodbridge 346
Seattle 300
Houston 262
Wilmington 241
Cambridge 227
Ann Arbor 207
Dearborn 115
Jacksonville 98
Princeton 76
Beijing 71
Dublin 70
Dong Ket 64
Udine 51
New York 45
San Diego 39
Washington 34
Izmir 27
Martignacco 26
Redmond 26
Ogden 24
Brussels 22
Des Moines 21
Zurich 15
Los Angeles 13
Phoenix 13
Boardman 12
Falls Church 12
Nanjing 12
Norwalk 12
Leawood 10
Timisoara 9
Hefei 8
Trieste 8
Augusta 7
Naples 7
Jinan 6
Warsaw 6
Codroipo 5
Kunming 5
Milan 5
Scafati 5
Simi Valley 5
Ardabil 4
Bovisio-Masciago 4
Edinburgh 4
Lomé 4
London 4
Menlo Park 4
Nanchang 4
Redwood City 4
Rome 4
Shenzhen 4
Tokyo 4
Zoppola 4
Cairo 3
Caserta 3
Dallas 3
Frankfurt am Main 3
Fuzhou 3
Grafing 3
Hebei 3
Montréal 3
Nutley 3
Paris 3
San Mateo 3
Shanghai 3
Tallinn 3
Toronto 3
Treviso 3
Wuhan 3
Bologna 2
Castelfranco Veneto 2
Cavaso del Tomba 2
Chengdu 2
Cincinnati 2
Como 2
Curno 2
Fairborn 2
Fremont 2
Guangzhou 2
Hangzhou 2
Hong Kong 2
Jinhua 2
Madrid 2
Monmouth Junction 2
Montreal 2
Novara 2
Pollenza 2
Prague 2
Pune 2
Romans d'Isonzo 2
Sagrado 2
Saint Petersburg 2
Shenyang 2
Treppo Grande 2
Venice 2
Waanrode 2
Totale 4.368
Nome #
In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis 172
Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer 137
MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme 131
First steps in the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma 128
Luminal-like HER2-negative stage IA breast cancer: A multicenter retrospective study on long-term outcome with propensity score analysis 126
Pattern of metastasis and outcome in patients with breast cancer 124
Treatment of metastatic breast cancer in a real-world scenario: Is progression-free survival with first line predictive of benefit from second and later lines? 120
The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer 117
Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme 113
Emerging Role of Genomics and Cell-Free DNA in Breast Cancer 113
Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy 110
Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach 109
Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example 106
Measures of outcome in metastatic breast cancer: insights from a real-world scenario. 105
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 103
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression 101
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy 100
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker 99
Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer 98
Do platinum salts fit all triple negative breast cancers? 98
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 95
Determinants of Last-line Treatment in Metastatic Breast Cancer 93
The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients 92
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle 90
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey 90
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 90
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 88
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 88
APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC 86
Complementary and alternative medicine in oncology [Le terapie alternative e complementari in oncologia] 85
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 85
Factors affecting patient's perception of anticancer treatments side-effects: an observational study. 84
null 84
Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside 84
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 80
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC 80
A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients 77
The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA) 77
Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors 76
Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations. 74
Monocyte-to-lymphocyte ratio in metastatic colorectal cancer: Prognostic role evaluation and cut-off definition 74
Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer 72
Risk factors and survival outcomes in patients with brain metastases from breast cancer 71
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper 71
Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation 70
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis 68
Monitoring metastatic breast cancer (M-MBC) during treatment: a GIM (Gruppo Italiano Mammella) survey 67
Neutrophil-to-lymphocyte ratio in metastatic breast cancer patients: relationship with tumor characteristics and survival 63
Low dose CT scan screening versus empiric surveillance in asbestos exposed subjects: Update of ATOM 002 study 62
Hype or hope? The strange case of platinum salts’ renaissance in breast cancer 61
Small luminal-like breast cancer: determinants of adjuvant chemotherapy use 60
Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer 55
Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study: Complementary and alternative medicine in oncology 53
Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models 53
Bevacizumab or PARP-Inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: A network meta-analysis 52
Time to surgery after neoadjuvant chemotherapy for early breast cancer 51
Longitudinal dynamics of circulating tumor cells and circulating tumor DNA for treatment monitoring in metastatic breast cancer 49
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC 48
The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells 46
Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC) 46
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer 41
Circulating tumor cell clusters are frequently detected in women with early-stage breast cancer 40
Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis 38
Lactate dehydrogenase as a prognostic biomarker in patients with hormone receptor-positive metastatic breast cancer treated with palbociclib: An exploratory cohort study 37
Image Analysis of Circulating Tumor Cells and Leukocytes Predicts Survival and Metastatic Pattern in Breast Cancer Patients 36
1781P Feasibility of an automated data solution for Binary Alignment Map (BAM) files generated through next generation sequencing (NGS) of circulating tumor DNA (ctDNA) 33
The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer 33
Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer 31
Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study 30
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer 30
Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study 28
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer 25
BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy 20
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 19
Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review 19
null 18
Landscape of circulating tumour DNA in metastatic breast cancer 18
Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools 18
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 16
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 16
Liquid Biopsy, an Everchanging Balance between Clinical Utility and Emerging Technologies 14
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 13
First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study 13
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long? 12
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 11
The use of serial circulating tumor DNA to detect resistance alterations in progressive metastatic breast cancer 10
Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial 7
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis 7
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation? 5
Clinical Perspectives in the Use of Liquid Biopsy in Metastatic Breast Cancer 5
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation 4
Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring? 3
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 1
Totale 5.851
Categoria #
all - tutte 19.901
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.901

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019210 0 0 0 0 0 0 0 0 0 0 125 85
2019/20201.682 57 104 60 214 140 216 188 176 206 173 89 59
2020/20211.306 52 131 91 229 114 72 85 143 81 69 108 131
2021/2022753 88 69 15 14 14 40 46 25 20 107 221 94
2022/2023928 87 101 28 124 99 212 3 72 125 10 48 19
2023/2024598 45 29 56 30 118 193 9 19 43 25 31 0
Totale 5.851